BPCE
ALNY icon

Bank Pictet & Cie (Europe)’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bank Pictet & Cie (Europe)’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,562
Closed -$383K – 156
2024
Q1 		$383K Buy
2,562
+835
+48% +$139K 0.01% 140
2023
Q4 		$331K Sell
1,727
-63
-4% -$10.7K 0.01% 222
2023
Q3 		$317K Sell
1,790
-23
-1% -$4.39K 0.01% 214
2023
Q2 		$344K Buy
+1,813
New +$359K 0.01% 212

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank Pictet & Cie (Europe)'s ALNY Position: Q2 2024 in Review

Bank Pictet & Cie (Europe) sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2024, closing a stake of 2,562 shares — an estimated $383K sold.

Bank Pictet & Cie (Europe) first reported a position in ALNY in Q2 2023 and held it in 4 quarters. The position peaked at $383K in Q1 2024. 522 funds tracked by Wall St. Rank hold ALNY as of Q2 2024.

  • Bank Pictet & Cie (Europe) reported no remaining Alnylam Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Bank Pictet & Cie (Europe) sold 2,562 Alnylam Pharmaceuticals shares in Q2 2024, an estimated $383K.
  • Bank Pictet & Cie (Europe) first reported a position in Alnylam Pharmaceuticals in Q2 2023 and held it in 4 quarters.
  • Bank Pictet & Cie (Europe)'s Alnylam Pharmaceuticals position peaked at $383K in Q1 2024.
  • 522 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2024.

Based on Bank Pictet & Cie (Europe)'s 13F filing for Q2 2024, filed 25 Jul 2024.